Improved birth rates are a stated priority for President Donald Trump's administration—but proposed budget cuts could make it harder for many Americans to afford a safe, healthy pregnancy.
Semler Scientific has offered to pay the Department of Justice nearly $30 million to settle federal healthcare fraud claims related to its peripheral artery disease test, QuantaFlo — a product used by UnitedHealth Group and other large insurers.
Eli Lilly on Thursday reported promising results for a daily pill that could serve as an alternative to injectable weight-loss and diabetes drugs. One thing hampering the GLP-1 drug boom is the fact that they're shots — not oral medications — which keeps some prospective patients from taking them. Lilly — which makes the diabetes drug Mounjaro and the weight-loss treatment Zepbound — reported positive Phase 3 trial results for the oral medication orforglipron.
UnitedHealth Group surprised investors with what its CEO said was an 'unusual and unacceptable' quarterly earnings miss, and it lowered its outlook for the full year due to higher-than-expected medical costs, sparking a more than 20% selloff in shares that reverberated across the sector. The company's first earnings miss since 2008 and accompanying bleak forecast sent investors to the exits, as they were hoping the U.S. insurer would maintain its profit outlook on expectations that demand for medical services would be similar to 2024.
Federal officials are circulating a draft budget proposal that would make dramatic additional cuts to federal health programs and serve as a roadmap for more mass firings. Though it's preliminary, the document gives an indication of the Trump administration’s priorities as it prepares its 2026 fiscal year budget proposal to Congress. The document indicates plans to deepen job and funding reductions across much of the federal government.